Johnson and Johnson Inc

Johnson & Johnson Inc
One Johnson & Johnson Plaza
New Brunswick, NJ 08933

USA

Phone: (732) 524-0400
Fax: (732) 214-0332
Web Site: http://www.jnj.com/

A. Company Profile

Johnson and Johnson (NYSE: JNJ) is one of world's leading pharmaceutical companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at Johnson and Johnson.

B. Products

Product Pipelines

1. Doxorubicin

Doxorubicin, adriamycin, is an antibiotics. It interacts with DNA and leads to disruption of DNA function.

2. Leustatin

Leustatin (cladribine, 2-chloro-2'-deoxy--D-adenosine) is a synthetic antineoplastic agent, a chlorinated purine nucleoside analog.

3. Procrit

Erythropoietin is a glycoprotein which stimulates red blood cell production. It is produced in the kidney and stimulates the division and differentiation of committed erythroid progenitors in the bone marrow. Procrit (Epoetin alfa), a 165 amino acid glycoprotein manufactured by recombinant DNA technology, has the same biological effects as endogenous erythropoietin.¹ It has a molecular weight of 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin.  

4. Zarnestra

Zarnestra is an agent that is classified as a farnesyl transferase inhibitor and is still in clinical trials. It is estimated that approximately 30% of leukemias have a mutated ras gene. The ras gene is a part of a biological pathway that transmits growth signals from the surface of a cell to within a cell. Normally, this growth pathway is under strict control. However, a mutation (alteration) within the ras gene can stimulate a cell to grow and replicate in an uncontrolled manner. Additionally, ras mutations have been implicated in suppressing another important growth regulatory pathway controlled by the p53 gene. The p53 gene is responsible for the suppression of cellular replication when a cell perceives a genetic mutation, such as in the development of cancer. Zarnestra has been designed to block a key enzyme (protein) that is involved in the mutated ras pathway. This slows down or stops the excessive replication of cancer cells caused by the mutated ras pathway. It is speculated that Zarnestra may create anti-cancer effects through other biological pathways as well.